Home   Business   Article

AstraZeneca announces positive results for phase III trial of Lynparza in advanced ovarian cancer

AstraZeneca and its collaborator MSD have announced more positive phase III trial results for Lynparza (olaparib).

The PAOLA-1 trial tested the drug in women with advanced ovarian cancer when added to the standard bevacizumab treatment, compared to using bevacizumab alone.

Dr Jose Baselga, AstraZeneca's executive vice-president, research & development oncology. Picture: AstraZeneca (15402456)
Dr Jose Baselga, AstraZeneca's executive vice-president, research & development oncology. Picture: AstraZeneca (15402456)

Those taking the two survived longer or lived without disease progression for longer than those on bevacizumab alone.

José Baselga, AstraZeneca’s executive vice president, oncology R&D, said: “The positive results from the PAOLA-1 trial demonstrate a clear potential benefit of adding Lynparza to the standard-treatment bevacizumab for women with advanced ovarian cancer.

“Following positive results from the SOLO-1 trial for women with a BRCA gene mutation, the PAOLA-1 trial marks yet another positive phase III trial for Lynparza as a 1st-line maintenance treatment for women with advanced ovarian cancer. We look forward to discussing the results with global health authorities as soon as possible.”

Ovarian cancer is the eighth most common cause of cancer death in women worldwide. There were nearly 300,000 new cases diagnosed in 2018 and around 185,000 deaths.

Lynparza, which is approved in 64 countries, is a first-in-class PARP inhibitor.

Earlier this month, there were encouraging phase III results for Lynparza for men with metastatic castration-resistant prostate cancer who had specific gene mutations.

Read more

Encouraging phase III trial results for AstraZeneca for lung cancer and prostate cancer drugs

AstraZeneca sales rise 12% - and busy second half of 2019 predicted

AstraZeneca and MSD share positive results for Lynparza in ovarian and pancreatic cancer trials

AstraZeneca immunotherapy for stage 3 lung cancer patients now available in England

How AstraZeneca achieved a fivefold increase in its new medicines success rate

First look inside AstraZeneca's new £500m-plus global HQ and R&D centre on Cambridge Biomedical Campus

AstraZeneca and Cancer Research UK launch joint Functional Genomics Centre in Cambridge


Iliffe Media does not moderate comments. Please click here for our house rules.

People who post abusive comments about other users or those featured in articles will be banned.

Thank you. Your comment has been received and will appear on the site shortly.


Terms of Comments

We do not actively moderate, monitor or edit contributions to the reader comments but we may intervene and take such action as we think necessary, please click here for our house rules.

If you have any concerns over the contents on our site, please either register those concerns using the report abuse button, contact us here.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies - Learn More